[1] Elul. Yamim Noraʼim. Sukot -- [2] Pesaḥ. Shevuʻot. Galut u-geʼulot. Ḥanukah. Purim.

[1] Elul. Yamim Noraʼim. Sukot -- [2] Pesaḥ. Shevuʻot. Galut u-geʼulot. Ḥanukah. Purim.

Axel Hägerström is one of the fairly few, if not the only, Swedish philosophers of international significance— yet, he remains in many ways unknown. A major contribution is his theory on the nature of norms and values, which came to be known as value-nihilism, celebrated by some and vehemently rejected by others: Hägerström was the first who formulated a noncognitivist moral theory and debate still continues about the exact significance, scope and implications of this theory. Together with Adolf Phalén, he (...) was one of the two founders of the so-called Uppsala School. He was also the inspirational source of Scandinavian legal realism. Hägerström can be said to be a significant thinker for three reasons: An extraordinary interpreter of his own time, he left his mark on his contemporaries; his thought continues to suggest interesting and contrasting readings, which is indicated by the fact that he is repeatedly re-read by new generations of scholars; finally, he developed general categories that we still use today to understand the world we now live in. This volume collects seventeen chapters of leading experts on Hägerström's philosophical legacy as well as a number of translations of published as well as unpublished manuscripts, collected on occasion of the centenary of Hägerström's prolusion, 'On the Truth of Moral Ideas'. (shrink)

We examine ethical considerations in access to facial transplantation (FT), with implications for promoting health equity. As a form of vascularised composite allotransplantation, FT is still considered innovative with a relatively low volume of procedures performed to date by a small number of active FT programmes worldwide. However, as numbers continue to increase and institutions look to establish new FT programmes, we anticipate that attention will shift from feasibility towards ensuring the benefits of FT are equitably available to those in (...) need. This manuscript assesses barriers to care and their ethical implications across a number of considerations, with the intent of mapping various factors relating to health equity and fair access to FT. Evidence is drawn from an evolving clinical experience as well as published scholarship addressing several dimensions of access to FT. We also explore novel concerns that have yet to be mentioned in the literature. (shrink)